Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 6, 2020; 8(3): 624-629
Published online Feb 6, 2020. doi: 10.12998/wjcc.v8.i3.624
Published online Feb 6, 2020. doi: 10.12998/wjcc.v8.i3.624
Camrelizumab (SHR-1210) leading to reactive capillary hemangioma in the gingiva: A case report
Qing Yu, Wen-Xia Wang, Department of Periodontology, School and Hospital of Stomatology, Shandong University, Shandong Key Laboratory of Oral Tissue Regeneration, Shandong Engineering Laboratory for Dental Materials and Oral Tissue Regeneration, Jinan 250012, Shandong Province, China
Author contributions: Yu Q and Wang WX performed the periodontal treatment; Wang WX collected the information of the patient; Yu Q drafted the manuscript; Wang WX read and revised the manuscript; both authors issued final approval for the version to be submitted.
Informed consent statement: Written informed consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Wen-Xia Wang, PhD, Doctor, Department of Periodontology, School and Hospital of Stomatology, Shandong University, Shandong Key Laboratory of Oral Tissue Regeneration, Shandong Engineering Laboratory for Dental Materials and Oral Tissue Regeneration, No. 44-1 Wenhua Road West, Jinan 250012, Shandong Province, China. wangwx@sdu.edu.cn
Received: December 15, 2019
Peer-review started: December 15, 2019
First decision: December 30, 2019
Revised: January 6, 2020
Accepted: January 11, 2020
Article in press: January 11, 2020
Published online: February 6, 2020
Processing time: 52 Days and 20.3 Hours
Peer-review started: December 15, 2019
First decision: December 30, 2019
Revised: January 6, 2020
Accepted: January 11, 2020
Article in press: January 11, 2020
Published online: February 6, 2020
Processing time: 52 Days and 20.3 Hours
Core Tip
Core tip: Camrelizumab (SHR-1210) is a kind of anti-PD-1 antibody. It was reported that a unique treatment-related adverse event was reactive capillary hemangioma. Notably, most reactive capillary hemangiomas occur in the skin, and this side effect is rarely seen in oral tissues. In this report, we describe the case of a patient who experienced gingival reactive capillary hemangioma during SHR-1210 treatment for lung cancer.